Precision BioSciences Inc reports results for the quarter ended March 31 - Earnings Summary

Precision Biosciences

15/05/2025 14:31

Precision BioSciences Inc DTIL.OQ reported a quarterly adjusted loss of $2.21​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -35 cents.  The mean expectation of three analysts for the quarter was for a loss of $1.72 per share. Wall Street expected results to range from $-2.42 to -43 cents per share.

Revenue fell 99.8% to $29.00 thousand from a year ago; analysts expected $5.00 million.

Precision BioSciences Inc's reported EPS for the quarter was a loss of $2.21​.

The company reported a quarterly loss of $20.57 million.

Precision BioSciences Inc shares had risen by 3.8% this quarter and gained 29.9% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 351.8% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Precision BioSciences Inc is $21.50

This summary was machine generated from LSEG data May 15 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-1.72
-2.21
Missed
Dec. 31 2024
-1.96
-2.22
Missed
Sep. 30 2024
-1.92
-2.25
Missed
Jun. 30 2024
-1.50
4.67
Beat